PetVivo Holdings, Inc. announced the successful completion of its $5,000,000 equity financing through a Series B Convertible Preferred Stock Offering. The company received the final $1,000,000 from the full exercise of a purchase option, bringing the total capital raised to $5,000,000.
The initial $600,000 of the offering proceeds was received on March 26, 2025, with subsequent exercises completing the full $5,000,000. This financing significantly strengthens PetVivo's balance sheet and provides essential capital for its strategic initiatives.
The proceeds from this offering are specifically earmarked to accelerate the commercialization of PetVivo's signature products, Spryng with OsteoCushion Technology and PrecisePRP. This funding is critical for expanding market penetration and unlocking further value for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.